Company intelligence / Profile preview
Insys Therapeutics
Chandler, Arizona, United Statesinsysrx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company's main product Subsys (sublingual fentanyl spray) was approved in 2012 for breakthrough pain in cancer patients. The company was involved in illegal marketing practices, bribing doctors to prescribe Subsys for off-label uses, which led to criminal convictions of executives and the company's bankruptcy in 2019.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Small moleculessynthetic cannabinoidsfentanyl-based medications
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Insys Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Insys Therapeutics.